Sanofi has announced a significant strategic decision to halt the development and forgo filing for approval of its immunology therapy,…
Read More
The Adult Epilepsy Market Poised for Substantial Growth Amidst Unmet Clinical Needs and Promising Pipeline Innovations
The adult epilepsy market across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan)…
Read More
BeOne Medicines Invests $300 Million to Expand Hopewell, New Jersey Manufacturing and Research Operations, Pushing Total US Investment Past $1 Billion
BeOne Medicines is significantly bolstering its presence in the United States with a substantial $300 million investment earmarked for the…
Read More
Evogene and ELEO Forge Strategic Alliance to Pioneer Next-Generation Oral PCSK9 Inhibitors for Cardiovascular Disease
Evogene and ELEO have officially announced a significant scientific collaboration poised to accelerate the discovery and development of novel oral…
Read More
Affinia Therapeutics Secures FDA Orphan Drug Designation for AFTX-201, a Promising Gene Therapy for BAG3-Associated Dilated Cardiomyopathy
Affinia Therapeutics has announced a significant milestone in the development of its investigational gene therapy, AFTX-201, with the US Food…
Read More
GSK Secures US Approval for Jideytro in ROS1-Positive Lung Cancer, Entering Competitive Market
Just days after finalizing a monumental $10.6 billion acquisition of Nuvalent, a move that significantly bolsters its oncology pipeline, GlaxoSmithKline…
Read More
Cellares and Papillon Therapeutics Partner to Automate Manufacturing of Investigational Therapy for Friedreich’s Ataxia
In a significant development for the rare disease community, Cellares and Papillon Therapeutics have announced a strategic collaboration aimed at…
Read More
European Commission Approves Expanded Use of Crysvita (burosumab) for Infants with X-Linked Hypophosphatemia
Kyowa Kirin EMEA, a subsidiary of Kyowa Kirin, has secured a significant approval from the European Commission (EC) to broaden…
Read More
Samsung Biologics Accelerates Global Expansion with Strategic US Acquisition and PolyPeptide Deal
South Korean contract development and manufacturing organization (CDMO) Samsung Biologics has embarked on a significant phase of global expansion, marked…
Read More
US President Donald Trump Plans to Introduce Steep Tariffs on Imported Generic Pharmaceuticals
Following a period of relative exemption from escalating trade tensions, the global generic pharmaceutical industry is now facing the prospect…
Read MoreYOU MAY HAVE MISSED
